Literature DB >> 19773584

Patient time requirements for anticoagulation therapy with warfarin.

Daniel E Jonas1, Betsy Bryant Shilliday, W Russell Laundon, Michael Pignone.   

Abstract

BACKGROUND: Most patients receiving warfarin are managed in outpatient office settings or anticoagulation clinics that require frequent visits for monitoring.
OBJECTIVE: To measure the amount and value of time required of patients for chronic anticoagulation therapy with warfarin.
DESIGN: /Participants. Prospective observation of a cohort of adult patients treated at a university-based anticoagulation program. Measurements. Participants completed a questionnaire and a prospective diary of the time required for 1 visit to the anticoagulation clinic, including travel, waiting, and the clinic visit. The authors reviewed subjects' medical records to obtain additional information, including the frequency of visits to the anticoagulation clinic. They used the human capital method to estimate the value of time.
RESULTS: Eighty-five subjects completed the study. The mean (median) total time per visit was 147 minutes (123). Subjects averaged 15 visits per year (14) and spent 39.0 hours (29.3) per year on their visits. Other anticoagulation-related activities, such as communication with providers, pharmacy trips, and extra time preparing food, added an average of 52.7 hours (19.0) per year. The mean annual value of patient time spent traveling, waiting, and attending anticoagulation visits was $707 (median $591). The mean annual value when also including other anticoagulation-related activities was $1799 (median $1132).
CONCLUSIONS: The time required of patients for anticoagulation visits was considerable, averaging approximately 2.5 hours per visit and almost 40 hours per year.
METHODS: for reducing patient time requirements, such as home-based testing, could reduce costs for patients, employers, and companions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773584      PMCID: PMC4181607          DOI: 10.1177/0272989X09343960

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  39 in total

1.  Screening for breast cancer: time, travel, and out-of-pocket expenses.

Authors:  R H Secker-Walker; P M Vacek; G J Hooper; D A Plante; A S Detsky
Journal:  J Natl Cancer Inst       Date:  1999-04-21       Impact factor: 13.506

Review 2.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors:  Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal:  Circulation       Date:  2003-04-01       Impact factor: 29.690

Review 3.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

4.  Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis.

Authors:  Sue Jowett; Stirling Bryan; Ellen Murray; Deborah McCahon; James Raftery; F D Richard Hobbs; David Fitzmaurice
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

Review 5.  [Portable coagulometers: a systematic review of the evidence on self-management of oral anticoagulant treatment].

Authors:  Oriol de Solà-Morales Serra; Josep Maria Elorza Ricart
Journal:  Med Clin (Barc)       Date:  2005-03-12       Impact factor: 1.725

6.  Benefits and costs of using HPV testing to screen for cervical cancer.

Authors:  Jeanne S Mandelblatt; William F Lawrence; Sharita Mizell Womack; Denise Jacobson; Bin Yi; Yi-ting Hwang; Karen Gold; James Barter; Keerti Shah
Journal:  JAMA       Date:  2002-05-08       Impact factor: 56.272

7.  Long-term treatment costs associated with implant-supported mandibular prostheses in edentulous patients.

Authors:  Nikolai J Attard; George A Zarb; Audrey Laporte
Journal:  Int J Prosthodont       Date:  2005 Mar-Apr       Impact factor: 1.681

8.  Estimating patient time costs associated with colorectal cancer care.

Authors:  K Robin Yabroff; Joan L Warren; Kevin Knopf; William W Davis; Martin L Brown
Journal:  Med Care       Date:  2005-07       Impact factor: 2.983

Review 9.  Personal costs associated with high-risk prenatal care attendance.

Authors:  M Stringer
Journal:  J Health Care Poor Underserved       Date:  1998-08

10.  Cost effectiveness of monitoring warfarin therapy using standard versus capillary prothrombin times.

Authors:  J E Ansell; A K Hamke; A Holden; N Knapic
Journal:  Am J Clin Pathol       Date:  1989-05       Impact factor: 2.493

View more
  10 in total

1.  Implementation and Quality Improvement of a Screening and Counseling Program for Unhealthy Alcohol Use in an Academic General Internal Medicine Practice.

Authors:  Daniel E Jonas; Thomas Miller; Shana Ratner; Brooke McGuirt; Carol E Golin; Catherine Grodensky; Emily Sturkie; Jennifer Kinley; Maureen Dale; Michael Pignone
Journal:  J Healthc Qual       Date:  2017 Jan/Feb       Impact factor: 1.095

2.  Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials.

Authors:  H L Tang; W L Shi; X G Li; T Zhang; S D Zhai; H G Xie
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

Review 3.  Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.

Authors:  Louise Justesen Hesselbjerg; Heidi Sjoelund Pedersen; Mikael Bergholdt Asmussen; Karin Dam Petersen
Journal:  J Med Econ       Date:  2013-05-15       Impact factor: 2.448

Review 4.  New oral anticoagulants and the cancer patient.

Authors:  Nicholas J Short; Jean M Connors
Journal:  Oncologist       Date:  2013-12-06

5.  Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center.

Authors:  Sweta Meet Patel; Tina Wang; Desire Lashalle Outler; Jennifer Elliott; Michael Knauss; Samuel K Peasah; Mikhail Akbashev
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

6.  Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation.

Authors:  Brian M Salata; David W Hutton; Deborah A Levine; James B Froehlich; Geoffrey D Barnes
Journal:  Am J Cardiol       Date:  2015-10-19       Impact factor: 2.778

7.  Implementation Science Workshop: primary care-based multidisciplinary readmission prevention program.

Authors:  Jamie Jurkiewicz Cavanaugh; Christine D Jones; Genevieve Embree; Katy Tsai; Thomas Miller; Betsy Bryant Shilliday; Brooke McGuirt; Robin Roche; Michael Pignone; Darren A DeWalt; Shana Ratner
Journal:  J Gen Intern Med       Date:  2014-05       Impact factor: 5.128

8.  Transitions of care in anticoagulated patients.

Authors:  Franklin Michota
Journal:  J Multidiscip Healthc       Date:  2013-06-20

9.  Contact frequency, travel time, and travel costs for patients with rheumatoid arthritis.

Authors:  Jan Sørensen; Louise Linde; Merete Lund Hetland
Journal:  Int J Rheumatol       Date:  2014-02-17

10.  Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Bleeding in Neurosurgical Patients: A Single-Center Experience.

Authors:  Jomantė Mačiukaitienė; Diana Bilskienė; Arimantas Tamašauskas; Adomas Bunevičius
Journal:  Medicina (Kaunas)       Date:  2018-04-25       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.